PeptideDB
es
EnglishEspañolDeutschPortuguês
PéptidosCategoríasCompararGuíasGlosario

Erythropoietin (EPO)

Ampliamente estudiado

EPO | Red Blood Cell Stimulating Hormone

Metabólico

Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production.

Datos moleculares y de investigación

Peso molecular
30,400 Da
Vida media
4-12 hours (IV), ~25 hours (SubQ)
Objetivos primarios
epo-receptor
Rutas (investigación)
injectable
Almacenamiento
2-8°C refrigerated; do not freeze; do not shake vials or syringes

Overview

Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow cells promotes survival and maturation of red blood cell precursors, increasing oxygen-carrying capacity. Due to performance-enhancing effects, it is banned in competitive sports.

Mechanism of action

EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production. Under hypoxic stress, endogenous EPO production can increase up to 1000-fold, demonstrating the body’s powerful oxygen-sensing regulatory system.

Key research findings

  • Stimulates red blood cell production
  • Increases oxygen-carrying capacity
  • FDA-approved for anemia treatment
  • Improves endurance capacity
  • Supports patients with chronic kidney disease
  • Helps chemotherapy-induced anemia
  • Well-characterized mechanism of action
  • Extensively studied safety profile

Research applications

Medical Indications (FDA-Approved)

  • CKD-Related Anemia — Primary FDA-approved indication for anemia secondary to chronic kidney disease.
  • Chemotherapy-Induced Anemia — FDA-approved for treating anemia in cancer patients receiving chemotherapy.
  • Surgical Blood Loss — Used to reduce need for blood transfusions in certain surgical settings.

Performance (Banned in Sports)

  • Endurance Enhancement — Increases oxygen delivery to muscles, improving endurance capacity. Banned by WADA.
  • Altitude Acclimatization — May accelerate adaptation to high altitude by increasing red blood cell mass.

Preguntas frecuentes sobre Erythropoietin (EPO)

Why is EPO banned in sports if it's FDA-approved as medicine?+

EPO is FDA-approved specifically for anemia in kidney disease and chemotherapy patients—narrow medical indications. It's banned in sports because it boosts oxygen delivery far beyond medical therapeutic levels, providing unfair endurance advantages. The performance-enhancing effects at doses used by athletes vastly exceed what's used medically.

At what hemoglobin level does EPO become dangerous?+

Medical guidelines recommend keeping hemoglobin below 11-12 g/dL during EPO therapy because higher levels significantly increase cardiovascular risks including blood clots, stroke, and heart attack. This ceiling exists because excessive oxygen-carrying capacity paradoxically becomes harmful, increasing blood viscosity dangerously.

Does EPO improve endurance without causing side effects?+

EPO absolutely improves endurance capacity by increasing red blood cell production and oxygen delivery. However, it commonly causes water retention, joint pain, headaches, and hypertension. More concerning are thromboembolic events (blood clots) and theoretical tumor progression risk with higher doses used for performance enhancement.

How long after stopping EPO do benefits disappear?+

EPO's effects begin diminishing once injections stop as red blood cells have a natural 120-day lifespan. Hemoglobin returns toward baseline within 2-3 weeks of discontinuation. Most performance benefits fade quickly, making continued use necessary for sustained effects, which is why athletes faced testing challenges in endurance sports.

References

  1. [1]Erythropoietin regulation of red blood cell productionPMC/NCBI
  2. [2]Erythropoietin Stimulating AgentsStatPearls (NCBI Bookshelf)
  3. [3]Erythropoiesis-stimulating agents and other methods to enhance oxygen transportPMC
  4. [4]The mechanism of erythropoietin actionPubMed

Péptidos relacionados

5-Amino-1MQ

Preclinical

NNMT Inhibitor | Longevity & Metabolic Enhancement

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.

LongevidadMetabólicoPérdida de Peso

AICAR

Limited research

5-Aminoimidazole-4-carboxamide Ribonucleotide | AMPK Activator

AICAR is a cell-permeable nucleoside analog that activates AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis.

MetabólicoRendimiento

AOD-9604

Well studied

Modified hGH Fragment | Fat Loss Peptide

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone.

Pérdida de PesoMetabólico

BAM-15

Moderate research

Mitochondrial Uncoupler | Metabolic Enhancer

BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders.

Pérdida de PesoMetabólico